HRP20110194T1 - Ciklopropil fuzionirani indolobenzazepini kao inhibitori hcv ns5b - Google Patents
Ciklopropil fuzionirani indolobenzazepini kao inhibitori hcv ns5b Download PDFInfo
- Publication number
- HRP20110194T1 HRP20110194T1 HR20110194T HRP20110194T HRP20110194T1 HR P20110194 T1 HRP20110194 T1 HR P20110194T1 HR 20110194 T HR20110194 T HR 20110194T HR P20110194 T HRP20110194 T HR P20110194T HR P20110194 T1 HRP20110194 T1 HR P20110194T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- hcv
- image
- inhibitors
- hydrogen
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 7
- JYGUARFTLQSWDG-UHFFFAOYSA-N 3,12-diazatetracyclo[9.7.0.02,8.013,18]octadeca-1,3,5,7,9,11,13,15,17-nonaene Chemical compound C1=CC=NC2=C3C4=CC=CC=C4N=C3C=CC2=C1 JYGUARFTLQSWDG-UHFFFAOYSA-N 0.000 title 1
- 101710112514 Host translation inhibitor 5b Proteins 0.000 title 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims abstract 26
- 150000001875 compounds Chemical class 0.000 claims abstract 23
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 17
- 239000001257 hydrogen Substances 0.000 claims abstract 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 12
- -1 hydroxy, benzyloxy Chemical group 0.000 claims abstract 9
- 150000003839 salts Chemical class 0.000 claims abstract 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 6
- 125000000547 substituted alkyl group Chemical group 0.000 claims abstract 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 5
- 125000003342 alkenyl group Chemical group 0.000 claims abstract 5
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims abstract 4
- 125000004193 piperazinyl group Chemical group 0.000 claims abstract 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims abstract 3
- 125000002393 azetidinyl group Chemical group 0.000 claims abstract 3
- 125000001475 halogen functional group Chemical group 0.000 claims abstract 3
- 125000002757 morpholinyl group Chemical group 0.000 claims abstract 3
- 125000003386 piperidinyl group Chemical group 0.000 claims abstract 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims abstract 3
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims abstract 3
- 125000003282 alkyl amino group Chemical group 0.000 claims abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 2
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 claims abstract 2
- 125000004692 haloalkylcarbonyl group Chemical group 0.000 claims abstract 2
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 239000012268 protein inhibitor Substances 0.000 claims 5
- 229940121649 protein inhibitor Drugs 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- 108010036941 Cyclosporins Proteins 0.000 claims 2
- 229940122750 HCV entry inhibitor Drugs 0.000 claims 2
- 229940124683 HCV polymerase inhibitor Drugs 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 108060004795 Methyltransferase Proteins 0.000 claims 2
- 101800001019 Non-structural protein 4B Proteins 0.000 claims 2
- 101800001014 Non-structural protein 5A Proteins 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 2
- 229930182912 cyclosporin Natural products 0.000 claims 2
- 239000003966 growth inhibitor Substances 0.000 claims 2
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 claims 2
- 229940047124 interferons Drugs 0.000 claims 2
- 229940047122 interleukins Drugs 0.000 claims 2
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 239000003001 serine protease inhibitor Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80112506P | 2006-05-17 | 2006-05-17 | |
| US80200506P | 2006-05-19 | 2006-05-19 | |
| US85208406P | 2006-10-16 | 2006-10-16 | |
| US89475707P | 2007-03-14 | 2007-03-14 | |
| PCT/US2007/068209 WO2007136982A1 (en) | 2006-05-17 | 2007-05-04 | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110194T1 true HRP20110194T1 (hr) | 2011-04-30 |
Family
ID=38512732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110194T HRP20110194T1 (hr) | 2006-05-17 | 2011-03-16 | Ciklopropil fuzionirani indolobenzazepini kao inhibitori hcv ns5b |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7456166B2 (xx) |
| EP (1) | EP2024375B1 (xx) |
| JP (1) | JP5284952B2 (xx) |
| KR (1) | KR101417145B1 (xx) |
| AR (1) | AR061008A1 (xx) |
| AT (1) | ATE501156T1 (xx) |
| AU (1) | AU2007253998B2 (xx) |
| BR (1) | BRPI0711821A2 (xx) |
| CA (1) | CA2651690C (xx) |
| CY (1) | CY1111526T1 (xx) |
| DE (1) | DE602007013036D1 (xx) |
| DK (1) | DK2024375T3 (xx) |
| EA (1) | EA015286B1 (xx) |
| HK (1) | HK1122814A1 (xx) |
| HR (1) | HRP20110194T1 (xx) |
| IL (1) | IL195025A (xx) |
| MX (1) | MX2008014435A (xx) |
| NO (1) | NO341663B1 (xx) |
| NZ (1) | NZ572555A (xx) |
| PE (1) | PE20080070A1 (xx) |
| PL (1) | PL2024375T3 (xx) |
| SI (1) | SI2024375T1 (xx) |
| TW (1) | TWI401244B (xx) |
| WO (1) | WO2007136982A1 (xx) |
| ZA (1) | ZA200809548B (xx) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1688420A4 (en) * | 2003-11-19 | 2008-10-22 | Japan Tobacco Inc | 5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR |
| US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
| US7521443B2 (en) * | 2006-05-17 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| CN101490054B (zh) * | 2006-05-25 | 2012-05-16 | 百时美施贵宝公司 | 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 |
| US7541351B2 (en) * | 2007-01-11 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7541352B2 (en) * | 2007-02-02 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7517872B2 (en) * | 2007-02-22 | 2009-04-14 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7998951B2 (en) * | 2007-03-05 | 2011-08-16 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
| WO2008111978A1 (en) | 2007-03-13 | 2008-09-18 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors |
| US7541353B2 (en) * | 2007-03-14 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7547690B2 (en) * | 2007-03-14 | 2009-06-16 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US7538102B2 (en) * | 2007-03-14 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US7521444B2 (en) * | 2007-03-14 | 2009-04-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7538103B2 (en) * | 2007-03-15 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| CA2686051A1 (en) | 2007-05-04 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Combination therapy for the treatment of hcv infection |
| US7652004B2 (en) * | 2007-08-09 | 2010-01-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8143243B2 (en) * | 2007-08-09 | 2012-03-27 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7642251B2 (en) * | 2007-08-09 | 2010-01-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| SI2209789T1 (sl) * | 2007-11-20 | 2012-06-29 | Bristol Myers Squibb Co | Ciklopropil zliti indolobenzazepin hcv ns5b inhibitorji |
| US8124601B2 (en) | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US8129367B2 (en) * | 2007-11-21 | 2012-03-06 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| WO2009076747A1 (en) | 2007-12-19 | 2009-06-25 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| DK2238142T3 (da) * | 2007-12-24 | 2012-10-08 | Janssen R & D Ireland | Makrocykliske indoler som hepatitis C-virusinhibitorer |
| WO2009120890A1 (en) * | 2008-03-27 | 2009-10-01 | Bristol-Myers Squibb Company | Dioxolane and dioxolanone fused indolobenzadiazepine hcv ns5b inhibitors |
| WO2009120745A1 (en) * | 2008-03-27 | 2009-10-01 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis c |
| WO2009120733A1 (en) * | 2008-03-27 | 2009-10-01 | Bristol-Myers Squibb Company | Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors |
| US8133884B2 (en) * | 2008-05-06 | 2012-03-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| TWI454476B (zh) * | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物 |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| WO2010080874A1 (en) | 2009-01-07 | 2010-07-15 | Scynexis, Inc. | Cyclosporine derivative for use in the treatment of hcv and hiv infection |
| US8143244B2 (en) * | 2009-02-26 | 2012-03-27 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US9127010B2 (en) | 2010-06-24 | 2015-09-08 | Janssen Sciences Ireland Uc | Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid |
| US20120196794A1 (en) * | 2010-08-06 | 2012-08-02 | Bristol-Myers Squibb Company | Combinations of Hepatitis C Virus Inhibitors |
| CN103649079B (zh) | 2010-12-22 | 2016-11-16 | Abbvie公司 | 丙型肝炎抑制剂及其用途 |
| CN103380132B (zh) | 2010-12-30 | 2016-08-31 | 益安药业 | 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂 |
| JP2014502620A (ja) | 2010-12-30 | 2014-02-03 | エナンタ ファーマシューティカルズ インコーポレイテッド | 大環状ｃ型肝炎セリンプロテアーゼ阻害剤 |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US8716275B2 (en) * | 2011-10-20 | 2014-05-06 | Bristol-Myers Squibb Company | Compound for the treatment of hepatitis C |
| MX2015000563A (es) * | 2012-07-18 | 2015-08-06 | Bristol Myers Squibb Holdings Ireland | Nuevos metodos y compuestos intermediarios para la preparacion de (4bs,5ar)-12-ciclohexil-n-(n,n-dimitilsulfamoil)-3-metoxi-5a-((1r ,5s)-3-metil-3,8-diazabiciclo [3.2.1]octano-8-carbonil)-4b,5,5a,6- tetrahidrobenzo[3,4]ciclopropa[5,6]-azepino [1,2-a] indol-9-carboxamida. |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US753137A (en) * | 1904-02-23 | Dust-pan | ||
| US752354A (en) * | 1904-02-16 | Composition post | ||
| US756203A (en) * | 1903-11-14 | 1904-04-05 | Oliver E Barthel | Muffler. |
| JP4143669B2 (ja) | 2004-02-24 | 2008-09-03 | 日本たばこ産業株式会社 | ４環縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用 |
| US7153848B2 (en) * | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| US7348425B2 (en) | 2004-08-09 | 2008-03-25 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| DE502005002697D1 (de) | 2004-10-13 | 2008-03-13 | Merck Patent Gmbh | Als kinaseinhibitoren geeignete derivate des n,n'-diphenylharnstoffs |
| EP1807397A2 (en) * | 2004-10-26 | 2007-07-18 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Tetracyclic indole derivatives as antiviral agents |
| GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US7399758B2 (en) | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7473688B2 (en) | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
| US7456165B2 (en) * | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
| GB0608928D0 (en) * | 2006-05-08 | 2006-06-14 | Angeletti P Ist Richerche Bio | Therapeutic agents |
-
2007
- 2007-05-03 US US11/743,921 patent/US7456166B2/en not_active Expired - Fee Related
- 2007-05-04 MX MX2008014435A patent/MX2008014435A/es active IP Right Grant
- 2007-05-04 EP EP07761873A patent/EP2024375B1/en active Active
- 2007-05-04 KR KR1020087027866A patent/KR101417145B1/ko active IP Right Grant
- 2007-05-04 DE DE602007013036T patent/DE602007013036D1/de active Active
- 2007-05-04 AT AT07761873T patent/ATE501156T1/de active
- 2007-05-04 SI SI200730612T patent/SI2024375T1/sl unknown
- 2007-05-04 JP JP2009511151A patent/JP5284952B2/ja active Active
- 2007-05-04 BR BRPI0711821-0A patent/BRPI0711821A2/pt not_active IP Right Cessation
- 2007-05-04 NZ NZ572555A patent/NZ572555A/en unknown
- 2007-05-04 AU AU2007253998A patent/AU2007253998B2/en not_active Ceased
- 2007-05-04 CA CA2651690A patent/CA2651690C/en not_active Expired - Fee Related
- 2007-05-04 WO PCT/US2007/068209 patent/WO2007136982A1/en active Application Filing
- 2007-05-04 PL PL07761873T patent/PL2024375T3/pl unknown
- 2007-05-04 DK DK07761873.4T patent/DK2024375T3/da active
- 2007-05-04 EA EA200802346A patent/EA015286B1/ru not_active IP Right Cessation
- 2007-05-15 PE PE2007000585A patent/PE20080070A1/es active IP Right Grant
- 2007-05-17 TW TW096117512A patent/TWI401244B/zh not_active IP Right Cessation
- 2007-05-17 AR ARP070102138A patent/AR061008A1/es active IP Right Grant
-
2008
- 2008-10-30 IL IL195025A patent/IL195025A/en not_active IP Right Cessation
- 2008-11-04 NO NO20084637A patent/NO341663B1/no not_active IP Right Cessation
- 2008-11-07 ZA ZA2008/09548A patent/ZA200809548B/en unknown
-
2009
- 2009-03-31 HK HK09103021.8A patent/HK1122814A1/xx not_active IP Right Cessation
-
2011
- 2011-03-16 HR HR20110194T patent/HRP20110194T1/hr unknown
- 2011-06-03 CY CY20111100539T patent/CY1111526T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110194T1 (hr) | Ciklopropil fuzionirani indolobenzazepini kao inhibitori hcv ns5b | |
| JP2010515752A5 (xx) | ||
| JP2010521481A5 (xx) | ||
| JP2010521476A5 (xx) | ||
| RU2428428C9 (ru) | Серусодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с | |
| JP2010521482A5 (xx) | ||
| JP2010521483A5 (xx) | ||
| AR061053A1 (es) | Inhibidores ns5b del virus de hepatitis c de indolobenzazepina fusionados a ciclopropilo | |
| JP2010521484A5 (xx) | ||
| HRP20090627T1 (hr) | Inhibitori hcv ns3 proteaze | |
| AR065772A1 (es) | Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas. | |
| RS67204A (xx) | Tripeptidi koji sadrže hidroksiprolin etar supstituisanog hinolina za inhibiranje ns3 (hepatitis c) | |
| EP1771454A4 (en) | PEPTIDE ANALOGUE AS HEPATITIS C HEMMER | |
| TW200615275A (en) | Hepatitis C inhibitor dipeptide analogs | |
| ZA200210311B (en) | Novel petides as NS3-serine protease inhibitors of hepatitis C virus. | |
| PE20050940A1 (es) | Nuevos inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c | |
| GEP20125456B (en) | Azetidines as mek inhibitors for the treatment of proliferative diseases | |
| ZA200405341B (en) | Proline compounds a NS3-serine protease inhibitors. | |
| ATE413411T1 (de) | Substituierte cycloalkyl p1' hepatitis c virus inhibitoren | |
| AR057810A1 (es) | Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo y composicion farmaceutica | |
| ATE481106T1 (de) | Heterocyclische sulfonamid-hepatitis-c-virus- hemmer | |
| HUP0400456A2 (hu) | Hepatitis C vírus N-ciklikus P2 csoportokat tartalmazó makrociklusos NS3-szerin proteáz inhibitorai és ezeket tartalmazó gyógyszerkészítmények | |
| ZA200405304B (en) | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | |
| DE60336550D1 (de) | Inhibitoren des hepatitis-c-virus | |
| HK1140214A1 (en) | Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors |